This webinar, brought to you by Cytiva, will be hosted live and available on-demand.
Monday, September 28, 2026
11:00 AM - 12:00 PM ET
Tuesday, October 6th, 2026
10:30 AM IST / 1 PM SGT / 2 PM JST & KST / 3 PM AEST
Efficient recombinant adeno-associated virus (rAAV) manufacturing depends on robust upstream processes that maximize productivity while maintaining vector quality. As demand for gene therapies continues to grow, researchers are seeking strategies to improve viral vector yields without compromising process consistency, scalability, or product performance.
In this webinar, brought to you by Cytiva, Anne MacIntyre, Senior Scientist, Viral Vector R&D Upstream Applications at Cytiva, will discuss approaches for improving transient rAAV production in HEK293 suspension cultures. The session will examine strategies for increasing viral genome titers while maintaining comparable cell viability and full capsid percentages across multiple AAV serotypes. Attendees will also learn how these approaches can support scalable, reproducible upstream manufacturing workflows for gene therapy applications.
Topics to be covered
- Strategies for improving transient rAAV production
- Optimizing HEK293 suspension cell culture workflows
- Increasing viral genome titers across multiple AAV serotypes
- Maintaining vector quality during process optimization
- Scaling upstream viral vector manufacturing
- Supporting robust gene therapy manufacturing workflows
 |
Anne M. MacIntyre
|
